Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3828250 | 0.93 | EDNRA (0.63) | EDNRAEDNRB | |
| SCHEMBL2487362 | 0.91 | EDNRA (0.52) | EDNRAEDNRB | |
| SCHEMBL8007885 | 0.86 | EDNRA (0.55) | EDNRAEDNRB | |
| SCHEMBL2487364 | 0.84 | EDNRA (0.59) | EDNRAEDNRB | |
| SCHEMBL7787027 | 0.84 | EDNRA (0.53) | EDNRAEDNRB | |
| SCHEMBL1008387 | 0.83 | EDNRA (0.53) | EDNRAEDNRB | |
| SCHEMBL7793953 | 0.83 | EDNRA (0.64) | EDNRAEDNRB | |
| SCHEMBL2489314 | 0.83 | EDNRA (0.53) | EDNRAEDNRB | |
| SCHEMBL1009078 | 0.83 | EDNRA (0.66) | EDNRAEDNRB | |
| SCHEMBL1009939 | 0.81 | EDNRA (0.54) | EDNRAEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2072503-B1 | Process for the preparation of bosentan | DIPHARMA FRANCIS SRL (IT) | 2011-10-26 | — | — | EP | claimed |
| EP-2072503-A2 | Process for the preparation of bosentan | Dipharma Francis S.r.l. (IT) | 2009-06-24 | — | — | EP | claimed |
| US-20090156811-A1 | Process for the Preparation of Bosentan | DIPHARMA FRANCIS S.R.L. (IT) | 2009-06-18 | — | — | US | claimed |
| EP-2072503-B1 | Process for the preparation of bosentan | DIPHARMA FRANCIS SRL (IT) | 2011-10-26 | — | — | EP | disclosed |
| EP-2072503-A2 | Process for the preparation of bosentan | Dipharma Francis S.r.l. (IT) | 2009-06-24 | — | — | EP | disclosed |
| US-20090156811-A1 | Process for the Preparation of Bosentan | DIPHARMA FRANCIS S.R.L. (IT) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156811-A1 | Process for the Preparation of Bosentan | PAH, HBB, HBZ | EDNRA 32/4885EDNRB 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.